OCU410, a single-dose modifier gene therapy, demonstrated positive preliminary outcomes for the treatment of geographic atrophy in a phase 1/2 clinical trial, according to a press release from Ocugen.
“Currently available therapies require six to 12 injections per year, which places an unreasonable burden on patients and caregivers,” Shankar Musunuri, PhD, MBA, chairman of the board, CEO and co-founder of Ocugen, told Healio. “Additionally, these therapies come with notable safety considerations while not demonstrating significant benefit in visual function.”
The ArMaDa